Literature DB >> 22576346

Tumor growth control using red blood cells as the antigen delivery system and poly(I:C).

Alice Banz1, Magali Cremel, Amélie Mouvant, Nathalie Guerin, Françoise Horand, Yann Godfrin.   

Abstract

The goal of most current vaccines in tumor immunology is to induce an efficient immune response against the tumor cells. The use of red blood cells (RBCs) for the delivery of tumor-associated antigen to antigen-presenting cells is an innovative approach for cancer immunotherapy. The induction of antigen-specific immune responses after administration of antigen-loaded RBCs has been demonstrated previously in mice. In this paper, we show the utility of this delivery system for cancer immunotherapy in 2 tumor mouse models, using the E.G7-OVA and the B16F10 tumor cells. The non-self-antigen, ovalbumin, loaded in RBCs and the self-tumor antigen, tyrosinase-related protein 2, loaded in RBCs were tested in the E.G7-OVA and the B16F10 tumor models, respectively. We showed that not only protein but also peptide could be efficiently entrapped in RBCs by a controlled lysis/resealing process. In both antigen models, the administration of a small quantity of antigen loaded in RBCs combined with polyinosinic-polycytidylic acid induced an antigen-specific T-cell response and the control of tumor growth in mice, whereas the injection of the same quantity of free antigen did not. The intensity of the T-cell response was dependent on the concentrations of antigen entrapped and the treatment performed on the RBC membrane (antibody coating and heat treatment) to improve antigen delivery. In summary, these results support the use of RBCs as an antigen delivery system for a powerful cancer immunotherapy approach.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22576346     DOI: 10.1097/CJI.0b013e3182594352

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  7 in total

1.  Whole blood cells loaded with messenger RNA as an anti-tumor vaccine.

Authors:  Kyle K L Phua; David Boczkowski; Jens Dannull; Scott Pruitt; Kam W Leong; Smita K Nair
Journal:  Adv Healthc Mater       Date:  2013-12-16       Impact factor: 9.933

2.  Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy.

Authors:  Eliran Moshe Reuven; Shani Leviatan Ben-Arye; Hai Yu; Roberto Duchi; Andrea Perota; Sophie Conchon; Shirley Bachar Abramovitch; Jean-Paul Soulillou; Cesare Galli; Xi Chen; Vered Padler-Karavani
Journal:  ACS Nano       Date:  2019-03-11       Impact factor: 15.881

3.  Poly (I:C) enhances the anti-tumor activity of canine parvovirus NS1 protein by inducing a potent anti-tumor immune response.

Authors:  Shishir Kumar Gupta; Pavan Kumar Yadav; A K Tiwari; Ravi Kumar Gandham; A P Sahoo
Journal:  Tumour Biol       Date:  2016-05-21

Review 4.  Surface loading of nanoparticles on engineered or natural erythrocytes for prolonged circulation time: strategies and applications.

Authors:  Si-Qi Zhang; Qiang Fu; Yun-Jie Zhang; Jian-Xing Pan; Ling Zhang; Zhi-Rong Zhang; Zhen-Mi Liu
Journal:  Acta Pharmacol Sin       Date:  2021-03-26       Impact factor: 7.169

Review 5.  Drug-loaded erythrocytes: on the road toward marketing approval.

Authors:  Vanessa Bourgeaux; José M Lanao; Bridget E Bax; Yann Godfrin
Journal:  Drug Des Devel Ther       Date:  2016-02-11       Impact factor: 4.162

6.  Establishment of an erythroid progenitor cell line capable of enucleation achieved with an inducible c-Myc vector.

Authors:  Steven Mayers; Pablo Diego Moço; Talha Maqbool; Pamuditha N Silva; Dawn M Kilkenny; Julie Audet
Journal:  BMC Biotechnol       Date:  2019-04-15       Impact factor: 2.563

7.  Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in mice.

Authors:  Katarina Blagovic; Carolyne K Smith; Amritha Ramakrishnan; Lindsay Moore; David R Soto; Zachary Thompson; Adam P Stockmann; Sonia Kruszelnicki; Akshi Thakkar; Jason Murray; Sebastian Torres; Bersabel Wondimagegnhu; Roslyn Yi; Maisam Dadgar; Abdul M Paracha; Claire Page; Louise Clear; Omer A Chaudhry; Melissa Myint; Devin T Bridgen; Jonathan B Gilbert; Katherine J Seidl; Armon Sharei; Scott Loughhead; Howard Bernstein; Defne Yarar
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.